HK Inno.N releases its GERD drug K-CAB in Singapore

Holds symposium to elebrate K-CAB’s launch in Singapore

Professor Prakash Gyawali (Department of Gastroenterology at Barnes-Jewish Hospital, Washington University Hospital) is giving a lecture at the K-CAB Launch Symposium in Singapore

On the 4th, HK Inno.N announced that it had officially released its novel gastroesophageal reflux disease (GERD) treatment K-CAB in Singapore.

 

HK Inno.N held a symposium to celebrate K-CAB’s launch at the Conrad Centennial Singapore Hotel on August 31st.

 

K-CAB was approved in February in Singapore under the same brand name, K-CAB.

 

HK Inno.N will export the finished product to its local partner, United Italian Trading Corporation (UITC), which will be in charge of local sales and marketing of K-CAB in Singapore.

 

The symposium, which was held for gastroenterologists in Singapore, was hosted by UITC.

 

At the symposium, Professor Prakash Gyawali (Department of Gastroenterology at Barnes-Jewish Hospital, Washington University Hospital) and Professor Hwoon-Yong Jung (Department of Gastroenterology at Asan Medical Center) shared the latest knowledge in using K-CAB.

 

During his presentation, Professor Gyawali focused on the superiority and safety of K-CAB, emphasizing the drug’s rapid onset of action and safety in terms of hepatotoxicity over other P-CAB class drugs.

 

Professor Jung shared his prescription experience with K-CAB in Korea.

 

Professor Jung said, “K-CAB had provided a better treatment option for GERD patients in Korea.” K-CAB has been exported as a technology or finished product to 35 countries overseas.

 

Among them, the drug has been launched locally in China, Mongolia, the Philippines, Mexico, Indonesia, and Singapore.

 

Also, the company is preparing to launch K-CAB in Peru after receiving approval in July.

 

Dal-won Kwak, CEO of HK Inno.N, said, “Singapore’s pharmaceutical market stands out among Southeast Asian countries, as it has been showing 11% YoY growth for the past 3 years.

 

We will continue to work closely with our local partners to ensure the successful approval and launch of K-CAB overseas.

 

K-CAB, which was released in March 2019, is a new drug for gastroesophageal reflux disease (GERD) in the P-CAB (potassium-competitive acid blocker) class.

 

It has a new mechanism of action that inhibits gastric acid secretion by competitively binding to the proton pump and potassium ion located in the final stage of acid secretion.

 

Its sales exceeded KRW 100 billion in prescriptions in its 3rd year of release in 2021 and recorded sales in the KRW 100 billion range for 2 consecutive years thereafter.

 

Also, K-CAB posted prescriptions amounting to KRW 74.1 billion in the H1 this year, heralding a record that exceeds KRW 100 billion for three consecutive years.